Recent Updates
Recently added Catalysts
KPTI

Karyopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference

Key Takeaway: NEWTON, Mass., Feb. 11, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will participate in a
Price reaction · baseline $136.65 (2022-02-10 close) · hit after-hours · clean, no other KPTI news in the window
day 0 close
+12.2%
day 1
+21.6%
day 3 · peak
+32.6%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+105%
120-day peak, hindsight
Typical move
15.1%
average across 5 past catalysts
Cash runway
~8 mo
Medium dilution risk
Lead asset
Selinexor
Phase 2 · Acute Myeloid Leukemia (AML)

Full Press Release Details

NEWTON, Mass., Feb. 11, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. The conference is being conducted in a virtual format and the fireside chat will take place on Friday, February 18, 2022 at 1:40 p.m. ET.
A live webcast of the fireside chat, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following the event.
About Karyopharm Therapeutics
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
Last updated: Feb 11, 2022